What is Cyclerion Therapeutics, Inc.'s earnings per share (EPS)?

Cyclerion Therapeutics, Inc. (CYCN) reported diluted earnings per share of -$1.11 for fiscal year 2025. This represents a 8.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cyclerion Therapeutics, Inc. (CYCN) Financials

CYCN

FY2025 annual

Revenue $2.1M +3.7% YoY

Net Income -$3.5M -15.4% YoY

EPS (Diluted) -$1.11 +8.3% YoY

Operating Cash Flow -$3.3M +23.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CYCN SEC filings page.

Cyclerion Therapeutics, Inc. (CYCN) reported $2.1M in revenue for fiscal year 2025, up 3.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CYCN FY2025 2026-10-04

Cyclerion now operates with modest revenue, recurring cash outflows, and a balance sheet supported more by financing than operating earnings.

Revenue was nearly flat at $2.0M in FY2024 and $2.1M in FY2025, while the operating loss widened from $3.6M to $5.0M, indicating that recent activity has not yet translated into operating improvement. Yet operating cash flow improved from -$4.3M to -$3.3M, so the smaller cash outflow appears driven by factors other than stronger core profitability.

The 5.2x current ratio alongside just $0.9M of liabilities indicates that near-term obligations are not the main balance-sheet pressure. The reported liquidity measure equaled 31.1 months of the latest annual operating outflow, a historical comparison rather than an earnings capability.

FY2025 financing cash flow of $3.3M nearly matched the operating cash outflow of $3.3M, showing that external funding was important to the period’s cash position. Shares outstanding increased from 2.7M in FY2024 to 4.3M in FY2025, consistent with operations being supported partly through a larger equity base.

Financial Health Signals

Financial Health Score 59/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Cyclerion Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Cyclerion Therapeutics, Inc. held $8.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $3.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Cyclerion Therapeutics, Inc. scores 57/100 among other emerging companies.

Dilution

Cyclerion Therapeutics, Inc. had 4M shares outstanding at the end of fiscal year 2025, against 3M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Cyclerion Therapeutics, Inc. scores 29/100 among other emerging companies.

R&D Intensity

Cyclerion Therapeutics, Inc. spent $959K on research and development in fiscal year 2025, which was 13.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Cyclerion Therapeutics, Inc. scores 43/100 among other emerging companies.

Revenue Progress

Cyclerion Therapeutics, Inc. reported revenue of $2.1M in fiscal year 2025, against $2.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Cyclerion Therapeutics, Inc. scores 48/100 among other emerging companies.

Burn Trend

Cyclerion Therapeutics, Inc.'s operations used $3.3M of cash in fiscal year 2025, against $4.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Cyclerion Therapeutics, Inc. scores 83/100 among other emerging companies.

Balance Sheet

Cyclerion Therapeutics, Inc.'s cash, cash equivalents and investments came to $8.6M at the end of fiscal year 2025, against $900K of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Cyclerion Therapeutics, Inc. scores 96/100 among other emerging companies.

Altman Z-Score Distress

-28.50

Cyclerion Therapeutics, Inc. scores -28.50, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($15.7M) relative to total liabilities ($900K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Cyclerion Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Cyclerion Therapeutics, Inc. reported a net loss of $3.5M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$1.8M

YoY-441.7%

QoQ+44.8%

Cyclerion Therapeutics, Inc. reported -$1.8M in net income in Q2 2026. This represents a decrease of 441.7% from the same quarter a year earlier. Against the prior quarter it is up 44.8%.

EPS (Diluted)

-$0.41

YoY-272.7%

QoQ+46.1%

Cyclerion Therapeutics, Inc. earned -$0.41 per diluted share (EPS) in Q2 2026. This represents a decrease of 272.7% from the same quarter a year earlier. Against the prior quarter it is up 46.1%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$1.4M

YoY-184.7%

QoQ-15.3%

Cyclerion Therapeutics, Inc. recorded an outflow of $1.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 184.7% from the same quarter a year earlier. Against the prior quarter it is down 15.3%.

Cash & Debt

$1.4M

YoY-53.7%

QoQ-50.7%

5Y CAGR-54.4%

Cyclerion Therapeutics, Inc. held $1.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+40.3%

QoQ+8.1%

5Y CAGR-35.9%

Cyclerion Therapeutics, Inc. had 5M shares outstanding in Q2 2026. This represents an increase of 40.3% from the same quarter a year earlier. Against the prior quarter it is up 8.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-34.5%

YoY-30.7pp

QoQ+12.3pp

Cyclerion Therapeutics, Inc.'s ROE was -34.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 30.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures

QoQ-100.0%

Cyclerion Therapeutics, Inc. reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

CYCN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CYCN quarterly income statement

Metric	TTM	FY25S-4/A	FY24S-4/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Revenue	N/A	$2.1M+3.7%	$2.0M	$0-100.0%	$297K-92.5%	$3.9M+71.7%	$2.3M-49.1%	$4.5M	N/A
R&D Expenses	N/A	$959K+235.3%	$286K-81.1%	$1.5M-74.7%	$6.0M-84.1%	$37.6M-33.3%	$56.4M-40.7%	$95.1M	N/A
SG&A Expenses	$7.1M	$6.1M+14.0%	$5.3M-34.3%	$8.1M-36.8%	$12.9M-37.6%	$20.6M-28.4%	$28.8M-16.2%	$34.4M+24.9%	$27.5M
Operating Income	-$6.8M	-$5.0M-37.1%	-$3.6M+72.0%	-$13.0M+30.1%	-$18.5M+66.4%	-$55.2M+32.1%	-$81.3M+35.0%	-$125.0M	N/A
EBITDA	N/A	N/A	N/A	-$13.0M+29.9%	-$18.5M+66.2%	-$54.7M+30.7%	-$79.0M+35.5%	-$122.3M	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$6.7M	-$3.5M-15.4%	-$3.1M+41.9%	-$5.3M+88.1%	-$44.1M+14.7%	-$51.6M+33.6%	-$77.8M+36.8%	-$123.0M	N/A
EPS (Basic)	N/A	-$1.11+8.3%	-$1.21+46.2%	-$2.25+88.9%	-$20.28-1436.4%	-$1.32	N/A	N/A	N/A
EPS (Diluted)	-$1.66	-$1.11+8.3%	-$1.21+46.2%	-$2.25	-$20.28	-$1.32	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	3M+26.3%	3M+7.7%	2M	2M	39M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'26S-4/A	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'25S-4/A	Q4'24S-4/A	Q3'2410-Q
Revenue	N/A	$0-100.0%	$1.0M	$875K+351.0%	$93K	$81K	N/A	$194K
R&D Expenses	N/A	$730K+1927.8%	$519K	$348K+329.6%	$56K-46.7%	$36K-18.2%	N/A	$81K-86.0%
SG&A Expenses	$1.8M+3.6%	$2.5M+65.0%	$1.3M	$1.5M+23.5%	$1.7M+33.6%	$1.5M-4.6%	N/A	$1.2M-41.8%
Operating Income	-$1.8M-5.9%	-$3.2M-120.2%	-$838K	-$1.0M+10.8%	-$1.7M-20.8%	-$1.5M+10.0%	N/A	-$1.1M+81.2%
Net Income	-$1.8M-441.7%	-$3.2M-122.3%	-$799K	-$976K-35.0%	-$324K+75.5%	-$1.4M+7.3%	N/A	-$723K-109.6%
EPS (Basic)	-$0.41-272.7%	-$0.76-35.7%	-$0.19-186.4%	-$0.30-3.4%	-$0.11+79.2%	-$0.56+9.7%	$0.22+131.4%	-$0.29-109.4%
EPS (Diluted)	-$0.41-272.7%	-$0.76	-$0.19-186.4%	-$0.30-3.4%	-$0.11+79.2%	-$0.56+9.7%	$0.22+131.4%	-$0.29-110.7%
Diluted Shares (Avg)	4M+38.4%	4M	N/A	3M+27.7%	3M+22.4%	3M+2.5%	N/A	3M-9.3%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

CYCN Balance Sheet

CYCN quarterly balance sheet

Metric	FY25S-4/A	FY24S-4/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$10.0M+4.3%	$9.6M-28.4%	$13.4M-26.0%	$18.1M-69.5%	$59.3M-48.6%	$115.4M-38.1%	$186.5M+2419.6%	$7.4M
Current Assets	$4.6M+9.7%	$4.2M-47.3%	$8.0M-45.9%	$14.8M-73.3%	$55.5M-5.2%	$58.5M-42.2%	$101.2M+11412.7%	$879K
Cash & Equivalents	$3.2M+0.2%	$3.2M-57.3%	$7.6M-43.4%	$13.4M-75.2%	$54.0M-0.8%	$54.4M-42.7%	$94.9M	$0
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$1.0M+79.9%	$556K	$0-100.0%	$96K-4.0%	$100K	$0	N/A	N/A
Long-Term Investments	$5.3M0.0%	$5.3M0.0%	$5.3M	$0	$0	$0	$0	$0
Total Liabilities	$900K+24.1%	$725K-65.2%	$2.1M-72.6%	$7.6M-31.2%	$11.1M-80.2%	$55.9M-37.0%	$88.7M+397.3%	$17.8M
Current Liabilities	$900K+24.1%	$725K-65.2%	$2.1M-72.6%	$7.6M-31.2%	$11.1M-34.6%	$17.0M-7.1%	$18.2M+2.3%	$17.8M
Non-Current Liabilities	$0	$0	$0	$0	$0-100.0%	$38.9M-44.8%	$70.5M	$0
Total Equity	$9.1M+2.7%	$8.8M-21.6%	$11.3M+8.0%	$10.5M-78.3%	$48.2M-18.9%	$59.5M-39.1%	$97.7M+1035.7%	-$10.4M
Retained Earnings	-$271.0M-1.3%	-$267.5M-1.2%	-$264.4M-2.0%	-$259.2M-20.5%	-$215.1M-31.6%	-$163.4M-90.9%	-$85.6M	N/A

Metric	Q2'2610-Q	Q1'26S-4/A	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'25S-4/A	Q4'24S-4/A	Q3'2410-Q
Total Assets	$6.9M-26.0%	$8.5M-13.6%	$10.0M+4.3%	$10.4M+17.0%	$9.4M-6.9%	$9.8M-13.3%	$9.6M-28.4%	$8.9M-41.5%
Current Assets	$1.5M-62.3%	$3.1M-31.3%	$4.6M+9.7%	$5.1M+42.8%	$4.0M-14.7%	$4.5M-25.2%	$4.2M-47.3%	$3.5M-64.0%
Cash & Equivalents	$1.4M-53.7%	$2.8M-22.4%	$3.2M+0.2%	$4.6M+59.1%	$3.0M-34.5%	$3.6M-36.1%	$3.2M-57.3%	$2.9M-68.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$0-100.0%	$0-100.0%	$1.0M+79.9%	$100K+127.3%	$525K	$581K	$556K	$44K
Long-Term Investments	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%
Total Liabilities	$1.8M+130.4%	$1.7M+60.6%	$900K+24.1%	$877K+25.3%	$800K-37.6%	$1.1M-26.0%	$725K-65.2%	$700K-70.1%
Current Liabilities	$1.8M+130.4%	$1.7M+60.6%	$900K+24.1%	$877K+25.3%	$800K-37.6%	$1.1M-26.0%	$725K-65.2%	$700K-70.1%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$5.1M-40.6%	$6.8M-22.7%	$9.1M+2.7%	$9.5M+16.3%	$8.6M-2.4%	$8.8M-11.5%	$8.8M-21.6%	$8.2M-36.3%
Retained Earnings	-$276.0M-2.5%	-$274.2M-2.0%	-$271.0M-1.3%	-$270.2M-0.8%	-$269.2M-0.7%	-$268.9M-1.1%	-$267.5M-1.2%	-$268.0M-2.0%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

CYCN Cash Flow Statement

CYCN quarterly cash flow statement

Metric	TTM	FY25S-4/A	FY24S-4/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$4.5M	-$3.3M+23.5%	-$4.3M+79.6%	-$21.2M+47.7%	-$40.6M-11.2%	-$36.5M+49.6%	-$72.5M+29.1%	-$102.2M	N/A
Depreciation & Amortization	N/A	N/A	N/A	$0-100.0%	$65K-86.2%	$472K-79.5%	$2.3M-14.9%	$2.7M+76.7%	$1.5M
Stock-Based Compensation	N/A	$441K-29.4%	$625K-41.4%	$1.1M-82.9%	$6.3M-34.9%	$9.6M-35.9%	$15.0M-23.6%	$19.6M+57.9%	$12.4M
Capital Expenditures	N/A	N/A	N/A	N/A	$0-100.0%	$7K-99.5%	$1.5M-77.9%	$6.9M+100.3%	$3.4M
Free Cash Flow	N/A	N/A	N/A	N/A	-$40.6M-11.2%	-$36.5M+50.7%	-$74.0M+32.2%	-$109.1M	N/A
Investing Cash Flow	N/A	N/A	$0-100.0%	$10.4M	$0-100.0%	$1.5M+7994.4%	$18K+100.3%	-$6.7M-95.3%	-$3.4M
Financing Cash Flow	$2.9M	$3.3M	$0-100.0%	$5.0M+17224.1%	$29K-99.9%	$30.8M+9.6%	$28.1M-86.7%	$211.6M	N/A

Metric	Q2'2610-Q	Q1'26S-4/A	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'25S-4/A	Q4'24S-4/A	Q3'2410-Q
Operating Cash Flow	-$1.4M-184.7%	-$1.2M-21.5%	-$1.6M-538.6%	-$264K+84.6%	-$503K+54.5%	-$968K+48.3%	$360K+123.4%	-$1.7M+75.3%
Stock-Based Compensation	$51K-55.3%	$58K-49.1%	N/A	$118K-14.5%	$114K-38.0%	$114K-37.0%	N/A	$138K-13.2%
Capital Expenditures	$0	$66K	N/A	N/A	$0	$0	N/A	N/A
Free Cash Flow	-$1.4M-184.7%	-$1.2M-28.3%	N/A	N/A	-$503K	-$968K	N/A	N/A
Investing Cash Flow	$0	-$66K	N/A	N/A	$0	$0	$0	$0-100.0%
Financing Cash Flow	$0+100.0%	$825K-40.0%	$251K	$1.8M	-$130K	$1.4M	$0	$0

Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid, Share Buybacks.

CYCN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CYCN quarterly financial ratios

Metric	FY25S-4/A	FY24S-4/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Margin	-239.8%	-181.4%	N/A	-6242.4%	-1400.2%	-3539.4%	-2774.3%	N/A
Net Margin	-170.1%	-152.8%	N/A	-14841.1%	-1310.2%	-3388.6%	-2729.3%	N/A
Return on Equity	-38.8%-4.3pp	-34.5%+12.1pp	-46.6%+375.1pp	-421.7%-314.7pp	-107.0%+23.7pp	-130.8%-4.9pp	-125.9%	N/A
Return on Assets	-35.3%-3.4pp	-31.9%+7.4pp	-39.4%+204.5pp	-243.8%-156.8pp	-87.1%-19.6pp	-67.4%-1.5pp	-66.0%	N/A
Current Ratio	5.15-0.7x	5.83+2.0x	3.85+1.9x	1.94-3.1x	5.00+1.6x	3.45-2.1x	5.55+5.5x	0.05
Debt-to-Equity	0.100.0x	0.08-0.1x	0.18-0.5x	0.73+0.5x	0.23-0.7x	0.940.0x	0.91	N/A
Asset Turnover	0.210.0x	0.21+0.2x	0.000.0x	0.02-0.1x	0.070.0x	0.020.0x	0.02	N/A
FCF Margin	N/A	N/A	N/A	-13673.7%	-926.5%	-3223.6%	-2420.8%	N/A

Metric	Q2'2610-Q	Q1'26S-4/A	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'25S-4/A	Q4'24S-4/A	Q3'2410-Q
Operating Margin	N/A	N/A	-81.8%	-115.0%	-1797.9%	-1798.8%	N/A	-581.4%
Net Margin	N/A	N/A	-78.0%	-111.5%	-348.4%	-1764.2%	N/A	-372.7%
Return on Equity	-34.5%-30.7pp	-46.8%-30.5pp	-8.8%	-10.2%-1.4pp	-3.8%+11.3pp	-16.3%-0.7pp	N/A	-8.8%-67.6pp
Return on Assets	-25.3%-21.9pp	-37.4%-22.8pp	-8.0%	-9.4%-1.2pp	-3.5%+9.7pp	-14.5%-0.9pp	N/A	-8.1%-57.9pp
Current Ratio	0.82-4.2x	1.80-2.4x	5.15-0.7x	5.78+0.7x	5.03+1.3x	4.210.0x	5.83+2.0x	5.07+0.9x
Debt-to-Equity	0.36+0.3x	0.25+0.1x	0.100.0x	0.090.0x	0.09-0.1x	0.120.0x	0.08-0.1x	0.09-0.1x
Asset Turnover	N/A	0.000.0x	0.10	0.08+0.1x	0.010.0x	0.010.0x	N/A	0.020.0x
FCF Margin	N/A	N/A	N/A	N/A	-540.9%	-1195.1%	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Cyclerion Therapeutics, Inc. CYCN	FY2025	$2.1M	-$3.5M	N/A	$15.7M	59/100
Galmed Pharmaceuticals Ltd. GLMD	FY2025	N/A	-$10.3M	N/A	$4.9M	—
VYNE Therapeutics Inc. VYNE	FY2025	$570K	-$26.5M	N/A	$19.1M	—
Impact BioMedical, Inc. IBO	FY2025	$32K	-$11.8M	N/A	$41.4M	—
Dogwood Therapeutics, Inc. DWTX	FY2025	N/A	-$34.3M	N/A	$51.7M	—
AEON Biopharma, Inc. AEON	FY2025	N/A	N/A	N/A	$13.5M	—

Where Cyclerion Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Cyclerion Therapeutics, Inc.'s annual revenue?

Cyclerion Therapeutics, Inc. (CYCN) reported $2.1M in total revenue for fiscal year 2025. This represents a 3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cyclerion Therapeutics, Inc.'s revenue growing?

Cyclerion Therapeutics, Inc. (CYCN) revenue grew by 3.7% year-over-year, from $2.0M to $2.1M in fiscal year 2025.

Is Cyclerion Therapeutics, Inc. profitable?

No, Cyclerion Therapeutics, Inc. (CYCN) reported a net income of -$3.5M in fiscal year 2025.

What is Cyclerion Therapeutics, Inc.'s return on equity (ROE)?

Cyclerion Therapeutics, Inc. (CYCN) has a return on equity of -38.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cyclerion Therapeutics, Inc.'s operating cash flow?

Cyclerion Therapeutics, Inc. (CYCN) recorded an outflow of $3.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Cyclerion Therapeutics, Inc.'s total assets?

Cyclerion Therapeutics, Inc. (CYCN) had $10.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Cyclerion Therapeutics, Inc. spend on research and development?

Cyclerion Therapeutics, Inc. (CYCN) invested $959K in research and development during fiscal year 2025.

How many shares does Cyclerion Therapeutics, Inc. have outstanding?

Cyclerion Therapeutics, Inc. (CYCN) had 4M shares outstanding as of fiscal year 2025.

What is Cyclerion Therapeutics, Inc.'s current ratio?

Cyclerion Therapeutics, Inc. (CYCN) had a current ratio of 5.15 as of fiscal year 2025, which is generally considered healthy.

What is Cyclerion Therapeutics, Inc.'s debt-to-equity ratio?

Cyclerion Therapeutics, Inc. (CYCN) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cyclerion Therapeutics, Inc.'s return on assets (ROA)?

Cyclerion Therapeutics, Inc. (CYCN) had a return on assets of -35.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Cyclerion Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Cyclerion Therapeutics, Inc. (CYCN) held $8.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.3M over that year. Dividing the one by the other, the reported balance equals about 31 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Cyclerion Therapeutics, Inc.'s Altman Z-Score?

Cyclerion Therapeutics, Inc. (CYCN) has an Altman Z-Score of -28.50, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Cyclerion Therapeutics, Inc.'s Piotroski F-Score?

Cyclerion Therapeutics, Inc. (CYCN) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cyclerion Therapeutics, Inc.'s earnings high quality?

Cyclerion Therapeutics, Inc. (CYCN) reported a net loss of $3.5M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Cyclerion Therapeutics, Inc.?

Cyclerion Therapeutics, Inc. (CYCN) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.